Net Profit Surge Over 120 Percent NHU Sees Strong Growth with Key Exports Exempt from US Tariffs

On April 7, NHU (Xinhua Pharmaceutical) announced that its core vitamin and coenzyme Q10 product lines are included in the latest U.S. tariff exemption list, shielding a major portion of its exports from new duties. These include the VE, VA, VC, VAD3, VB, and coenzyme Q10 series, securing NHU’s international revenue streams.

Though approximately 50% of NHU’s total revenue comes from overseas markets, sales to the U.S. account for less than 10%, minimizing any material impact from recent trade tensions. The company emphasized that while global competition remains intense, innovation has been key to its resilience and growth over the years.

In its 2024 performance forecast, NHU estimates a net profit of 5.8 to 6.2 billion yuan, representing a year-on-year jump of over 114%, driven by strong sales and higher prices in its nutritional product line.

The company attributes this performance to its strategic focus on market expansion, risk control, and operational efficiency. By deepening its presence in nutrition, flavors, polymers, and APIs, and advancing functional chemicals in emerging industries like green energy, crop protection, and information tech, NHU aims to sustain high-quality growth across multiple sectors.

Backed by modern production bases in Zhejiang, Shandong, and Heilongjiang, and supported by global R&D and marketing networks, NHU is poised to extend its industrial chain and further cement its position as a global chemical innovation leader.